Pacritinib vs Ruxolitinib
Ruben A. Mesa, MD, chair, Hematology, deputy director, Mayo Clinic, discusses pacritinib vs ruxolitinib.
Mesa speaks about a study that used pacritinib, instead of ruxolitinib. This drug was not chosen for this study because ruxolitinib was not indicated for patients with a platelet count under 100,000, when the trial began.
Mesa explains the difficulty of comparing data from the two drugs, but he was able to say that there are many vital benefits for splenomegaly symptoms that were presented in both phase III studies.
Ruben A. Mesa, MD, chair, Hematology, deputy director, Mayo Clinic, discusses pacritinib vs ruxolitinib.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
